| Carlin Corsino, DO | |
|
155 Memorial Dr, Pinehurst, NC 28374 | |
| (910) 715-1000 | |
| Not Available |
| Full Name | Carlin Corsino |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Experience | 10 Years |
| Location | 155 Memorial Dr, Pinehurst, North Carolina |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1225453566 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | 2019-01650 (North Carolina) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Firsthealth Moore Regional Hospital | Pinehurst, NC | Hospital |
| Firsthealth Montgomery Memorial Hosp | Troy, NC | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Sandhills Emergency Physicians Pa | 8729062609 | 37 |
News Archive
The March 2013 issue (.pdf) of the Global Health Diplomacy Network's (GHD-NET) Health & Foreign Policy Bulletin is now available online.
CBD Expo Tour 2019 produced by Mace Media Group, one of the nation's largest diversified media and information companies in the cannabis space and publisher of Terpenes and Testing Magazine, today announced CBD Lion as the Headline Sponsor for CBD Expo MIDWEST in Indianapolis, Indiana to take place on March 15-16, 2019.
BerGenBio AS today announced the start of a Phase 1 Clinical Trial for BGB324, a first-in-class small molecule inhibitor of AXL tyrosine kinase. BGB324 is a highly selective, oral AXL inhibitor that blocks the epithelial-mesenchymal transition (EMT), which is a key driver of metastasis (cancer spread) and drug-resistance. The Phase 1 clinical trial of BGB324 is a single ascending dose study designed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of BGB324.
One of the most vexing aspects of the COVID-19 pandemic is doctors' inability to predict which newly hospitalized patients will go on to develop severe disease, including complications that require the insertion of a breathing tube, kidney dialysis or other intensive care.
Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. today announced results from two collaborative group-sponsored randomized, double-blind, placebo-controlled Phase 2 trials were presented at the 32nd Annual San Antonio Breast Cancer Symposium (SABCS).
› Verified 8 days ago
| Entity Name | Sandhills Emergency Physicians Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1003853409 PECOS PAC ID: 8729062609 Enrollment ID: O20040617000371 |
News Archive
The March 2013 issue (.pdf) of the Global Health Diplomacy Network's (GHD-NET) Health & Foreign Policy Bulletin is now available online.
CBD Expo Tour 2019 produced by Mace Media Group, one of the nation's largest diversified media and information companies in the cannabis space and publisher of Terpenes and Testing Magazine, today announced CBD Lion as the Headline Sponsor for CBD Expo MIDWEST in Indianapolis, Indiana to take place on March 15-16, 2019.
BerGenBio AS today announced the start of a Phase 1 Clinical Trial for BGB324, a first-in-class small molecule inhibitor of AXL tyrosine kinase. BGB324 is a highly selective, oral AXL inhibitor that blocks the epithelial-mesenchymal transition (EMT), which is a key driver of metastasis (cancer spread) and drug-resistance. The Phase 1 clinical trial of BGB324 is a single ascending dose study designed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of BGB324.
One of the most vexing aspects of the COVID-19 pandemic is doctors' inability to predict which newly hospitalized patients will go on to develop severe disease, including complications that require the insertion of a breathing tube, kidney dialysis or other intensive care.
Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. today announced results from two collaborative group-sponsored randomized, double-blind, placebo-controlled Phase 2 trials were presented at the 32nd Annual San Antonio Breast Cancer Symposium (SABCS).
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Carlin Corsino, DO 3551 Roger Brooke Dr, Medical Education, Fort Sam Houston, TX 78234-4504 Ph: () - | Carlin Corsino, DO 155 Memorial Dr, Pinehurst, NC 28374 Ph: (910) 715-1000 |
News Archive
The March 2013 issue (.pdf) of the Global Health Diplomacy Network's (GHD-NET) Health & Foreign Policy Bulletin is now available online.
CBD Expo Tour 2019 produced by Mace Media Group, one of the nation's largest diversified media and information companies in the cannabis space and publisher of Terpenes and Testing Magazine, today announced CBD Lion as the Headline Sponsor for CBD Expo MIDWEST in Indianapolis, Indiana to take place on March 15-16, 2019.
BerGenBio AS today announced the start of a Phase 1 Clinical Trial for BGB324, a first-in-class small molecule inhibitor of AXL tyrosine kinase. BGB324 is a highly selective, oral AXL inhibitor that blocks the epithelial-mesenchymal transition (EMT), which is a key driver of metastasis (cancer spread) and drug-resistance. The Phase 1 clinical trial of BGB324 is a single ascending dose study designed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of BGB324.
One of the most vexing aspects of the COVID-19 pandemic is doctors' inability to predict which newly hospitalized patients will go on to develop severe disease, including complications that require the insertion of a breathing tube, kidney dialysis or other intensive care.
Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. today announced results from two collaborative group-sponsored randomized, double-blind, placebo-controlled Phase 2 trials were presented at the 32nd Annual San Antonio Breast Cancer Symposium (SABCS).
› Verified 8 days ago
Don Robert Bahner Jr., MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 155 Memorial Dr, Pinehurst, NC 28374 Phone: 910-715-1000 | |
Alicia Cox, DO Emergency Medicine Medicare: Medicare Enrolled Practice Location: 155 Memorial Dr, Pinehurst, NC 28374 Phone: 302-733-1042 | |
Darrell Simpkins, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 155 Memorial Dr, Pinehurst, NC 28374 Phone: 910-715-1000 | |
Matthew Reinhardt, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 155 Memorial Dr, Pinehurst, NC 28374 Phone: 910-715-1000 | |
Ronald Milewski, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 155 Memorial Dr, Pinehurst, NC 28374 Phone: 910-692-8224 | |
Mary Peterson-suri, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 155 Memorial Dr, Pinehurst, NC 28374 Phone: 910-715-1000 |